Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

BHVN.US Logo

BHVN.US - Current Price

$11.12

Company Information

Company Name
Biohaven Pharmaceutical Holding Co Ltd
Sector
Healthcare
Industry
Biotechnology
Exchange
NYSE
ISIN: VGG111961055
CIK: 0001689813
Currency: USD
Full Time Employees: 256
Phone: 203 404 0410
Fiscal Year End: December
IPO Date: Sep 23, 2022
Description:

Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven Ltd. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Address:

215 Church Street, New Haven, CT, United States, 06510

Directors & Officers

Name Title Year Born
Dr. Vladimir Coric M.D. Chairman & CEO 1971
Mr. Matthew Buten Chief Financial Officer 1961
Dr. Bruce D. Car DACVP, Ph.D. Chief Scientific Officer 1962
Ms. Kimberly Gentile Senior Vice President of Clinical Operations 1966
Ms. Deb Young Senior Director of Regulatory Affairs & Operations NA
Mr. George C. Clark CPA VP & Chief Accounting Officer 1985
Ms. Jennifer Porcelli Vice President of Investor Relations NA
Mr. Warren Volles J.D. General Counsel & Chief Legal Officer NA
Mr. Clifford Bechtold M.S. President, GM of Biohaven Ireland & Chief Compliance Officer NA
Mr. John Tilton Chief Commercial Officer of Rare Diseases 1968

Shares Statistics

Shares Outstanding: 132.69M
Shares Float: 92.90M
% Insiders: 952.00%
% Institutions: 6,488.50%
Short % Float: 16.52%

Valuation Metrics

Enterprise Value: $1.62B
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $1.57B
EBITDA: $-771.87M
Book Value: $-0.16
Earnings/Share: $-7.52
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -106.25%
ROE (TTM): -522.08%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

Date EPS Actual EPS Estimate Difference Surprise %
Dec 31, 2025 0.00 -1.37 N/A 10,000.00%
Sep 30, 2025 -1.64 -1.88 N/A 1,276.60%
Jun 30, 2025 -1.94 -1.94 N/A 0.00%
Mar 31, 2025 -2.17 -1.70 N/A -2,764.71%
Dec 31, 2024 -1.71 -1.60 N/A -687.50%
Sep 30, 2024 -1.74 -1.70 N/A -235.29%
Jun 30, 2024 -3.50 -1.78 N/A -9,662.92%
Mar 31, 2024 -2.20 -1.57 N/A -4,012.74%
Dec 31, 2023 -1.81 -1.41 N/A -2,836.88%
Sep 30, 2023 -1.50 -1.34 N/A -1,194.03%
Jun 30, 2023 -1.32 -1.21 N/A -909.09%
Mar 31, 2023 -1.03 -1.41 N/A 2,695.04%
Dec 31, 2022 -3.32 -1.22 N/A -17,213.11%
Sep 30, 2022 -1.75 -2.34 N/A 2,521.37%
Jun 30, 2022 -6.21 -2.58 N/A -14,069.77%
Mar 31, 2022 -2.97 -2.53 N/A -1,739.13%
Dec 31, 2021 -3.01 -2.04 N/A -4,754.90%
Sep 30, 2021 -2.63 -2.40 N/A -958.33%
Jun 30, 2021 -3.23 -2.72 N/A -1,875.00%
Mar 31, 2021 -4.21 -2.82 N/A -4,929.08%
Dec 31, 2020 -3.62 -2.97 N/A -2,188.55%
Sep 30, 2020 -3.27 -2.89 N/A -1,314.88%
Jun 30, 2020 -3.08 -2.61 N/A -1,800.77%
Mar 31, 2020 -3.07 -2.34 N/A -3,119.66%
Dec 31, 2019 -2.85 -1.87 N/A -5,240.64%
Sep 30, 2019 -2.04 -1.57 N/A -2,993.63%
Jun 30, 2019 -4.67 -1.92 N/A -14,322.92%
Mar 31, 2019 -1.41 -1.48 N/A 472.97%
Dec 31, 2018 -1.34 -1.21 N/A -1,074.38%
Sep 30, 2018 -1.53 -1.07 N/A -4,299.07%
Jun 30, 2018 -1.01 -1.18 N/A 1,440.68%
Mar 31, 2018 -2.32 -1.14 N/A -10,350.88%
Dec 31, 2017 -0.75 -1.20 N/A 3,750.00%
Sep 30, 2017 -1.19 -1.10 N/A -818.18%
Jun 30, 2017 -1.78 -0.61 N/A -19,180.33%
Mar 31, 2017 -1.74 -0.79 N/A -12,025.32%
Dec 31, 2016 0.00 0.00 N/A N/A
Dec 31, 1990 -4.67 0.00 N/A N/A

Balance Sheet (Yearly)

Date Cash Total Debt Total Assets Total Liabilities Total Equity
2024-12-31 $99.13M $N/A $615.11M $191.67M $423.44M
2023-12-31 $248.40M $N/A $513.21M $85.24M $427.98M
2022-12-31 $204.88M $N/A $661.78M $123.01M $538.77M
2021-12-31 $76.06M $N/A $142.06M $47.37M $34.69M
2020-12-31 $82.51M $N/A $111.50M $34.72M $16.78M
2019-12-31 $316.73M $N/A $344.26M $351.69M $-7.42M
2018-12-31 $264.25M $N/A $290.01M $139.09M $150.92M
2017-12-31 $131.47M $N/A $146.89M $14.92M $131.97M

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 04, 2025 N/A N/A N/A N/A N/A N/A
Dec 30, 2024 N/A N/A N/A N/A N/A N/A

Watchlist

0

No stocks in watchlist